Literature DB >> 21484874

Nonmotor manifestations of dystonia: a systematic review.

Daniel J Kuyper1, Veronica Parra, Shanae Aerts, Michael S Okun, Benzi M Kluger.   

Abstract

Nonmotor symptoms are increasingly recognized as important determinants of quality of life and disability in a wide range of movement disorders. There is a limited body of research suggesting that many of these symptoms are also commonly associated with primary and other genetic forms of dystonia. However, the significance, etiology, pathophysiology, and treatment of these symptoms remain poorly described. The following is a review of the literature that focuses primarily on the association of these types of dystonia with psychiatric disorders, cognition, sleep, pain, and autonomic symptoms. We will also discuss potential mechanisms and approaches to treatment for nonmotor features of dystonia.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 21484874      PMCID: PMC3652664          DOI: 10.1002/mds.23709

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  86 in total

Review 1.  Antimuscarinic drugs in the treatment of movement disorders.

Authors:  S Fahn; R Burke; Y Stern
Journal:  Prog Brain Res       Date:  1990       Impact factor: 2.453

2.  Preservation of cognitive function in dystonia treated by pallidal stimulation.

Authors:  B Pillon; C Ardouin; K Dujardin; P Vittini; A Pelissolo; O Cottencin; L Vercueil; J-L Houeto; P Krystkowiak; Y Agid; A Destée; P Pollak; M Vidailhet
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

3.  The effect of nocturnal physiological sleep on various movement disorders.

Authors:  R Silvestri; P De Domenico; A E Di Rosa; P Bramanti; S Serra; R Di Perri
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

Review 4.  The diagnosis of dystonia.

Authors:  Howard L Geyer; Susan B Bressman
Journal:  Lancet Neurol       Date:  2006-09       Impact factor: 44.182

5.  Personality in torticollis: a controlled study.

Authors:  M Jahanshahi; C D Marsden
Journal:  Psychol Med       Date:  1988-05       Impact factor: 7.723

6.  Spastic dysphonia. I. Voice, neurologic, and psychiatric aspects.

Authors:  A E Aronson; J R Brown; E M Litin; J S Pearson
Journal:  J Speech Hear Disord       Date:  1968-08

7.  Higher prevalence of obsessive-compulsive symptoms in patients with blepharospasm than in patients with hemifacial spasm.

Authors:  A Broocks; A Thiel; D Angerstein; D Dressler
Journal:  Am J Psychiatry       Date:  1998-04       Impact factor: 18.112

8.  Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: implications for treatment strategies.

Authors:  A E Taylor; A E Lang; J A Saint-Cyr; D E Riley; R Ranawaya
Journal:  Clin Neuropharmacol       Date:  1991-02       Impact factor: 1.592

Review 9.  Neuropsychology of obsessive-compulsive disorder: a review and treatment implications.

Authors:  Scott Greisberg; Dean McKay
Journal:  Clin Psychol Rev       Date:  2003-02

10.  Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.

Authors:  Jau-Shin Lou; Greg Kearns; Theodore Benice; Barry Oken; Gary Sexton; John Nutt
Journal:  Mov Disord       Date:  2003-10       Impact factor: 10.338

View more
  45 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

Review 2.  Designing clinical trials for dystonia.

Authors:  Wendy R Galpern; Christopher S Coffey; Alberto Albanese; Ken Cheung; Cynthia L Comella; Dixie J Ecklund; Stanley Fahn; Joseph Jankovic; Karl Kieburtz; Anthony E Lang; Michael P McDermott; Jeremy M Shefner; Jan K Teller; John L P Thompson; Sharon D Yeatts; H A Jinnah
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  Long-term neuropsychiatric outcomes after pallidal stimulation in primary and secondary dystonia.

Authors:  Sara Meoni; Mateusz Zurowski; Andres M Lozano; Mojgan Hodaie; Yu-Yan Poon; Melanie Fallis; Valerie Voon; Elena Moro
Journal:  Neurology       Date:  2015-07-08       Impact factor: 9.910

Review 4.  Diagnosis and treatment of dystonia.

Authors:  H A Jinnah; Stewart A Factor
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

5.  Neurocognitive profile of patients with X-linked dystonia-parkinsonism.

Authors:  Roland Dominic G Jamora; Cezar Thomas R Suratos; Jesi Ellen C Bautista; Gail Melissa I Ramiro; Ana Westenberger; Christine Klein; Lourdes K Ledesma
Journal:  J Neural Transm (Vienna)       Date:  2021-02-27       Impact factor: 3.575

6.  Impaired heart rate variability in cervical dystonia is associated to depression.

Authors:  F Hentschel; D Dressler; M Abele; S Paus
Journal:  J Neural Transm (Vienna)       Date:  2016-11-05       Impact factor: 3.575

7.  Social cognition and idiopathic isolated cervical dystonia.

Authors:  Kristína Czekóová; Petra Zemánková; Daniel J Shaw; Martin Bareš
Journal:  J Neural Transm (Vienna)       Date:  2017-04-25       Impact factor: 3.575

8.  Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study.

Authors:  Daniela Di Giuda; Giovanni Camardese; Anna Rita Bentivoglio; Fabrizio Cocciolillo; Arianna Guidubaldi; Lorella Pucci; Isabella Bruno; Luigi Janiri; Alessandro Giordano; Alfonso Fasano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-14       Impact factor: 9.236

Review 9.  Sensory aspects of movement disorders.

Authors:  Neepa Patel; Joseph Jankovic; Mark Hallett
Journal:  Lancet Neurol       Date:  2014-01       Impact factor: 44.182

10.  Clinimetric testing of the comprehensive cervical dystonia rating scale.

Authors:  Cynthia L Comella; Joel S Perlmutter; Hyder A Jinnah; Tracy A Waliczek; Ami R Rosen; Wendy R Galpern; Charles A Adler; Richard L Barbano; Stewart A Factor; Christopher G Goetz; Joseph Jankovic; Stephen G Reich; Ramon L Rodriguez; William L Severt; Mateusz Zurowski; Susan H Fox; Glenn T Stebbins
Journal:  Mov Disord       Date:  2016-03-12       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.